Rheuma-Study

Currently there are about 65.000 people in Austria suffering on rheumatoid arthritis.

The therapies for the patients are conducted with biologics and the progress for each individual patient will be monitored and evaluated. The average duration of each treatment and its efficency turnes out to be very volatile and the patients response is individual in the same way. The costs for each patients therapy can vary therefore. A special Set of biomarkers should help to reduce the tiem between the individual therapy-trains with biologics. A special and individualized therapy will be established and can help to reach the target for reduction of therapy costs and duration of treatment. The patients therefore can benefit from the shortening of the duration’s reduction.

Example of a typical Genomics-System for Biomarker Development.